NASDAQ : OKYO
OKYO Pharma Limited — Financial statements
Healthcare · Biotechnology · United Kingdom
Last price 1.5 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 78.72M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year April - March; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Cost of Revenue | 6.69M | 6.69M | 4.84M | 7.51M | 6.85M | 4.61M |
| Gross Profit | -6.69M | -6.69M | -4.84M | -7.51M | -6.85M | -4.61M |
| Research & Development | 1.81M | 1.81M | 2.25M | 8.24M | 6.34M | 1.61M |
| Operating Expenses | 1.81M | 1.81M | 2.25M | 8.24M | 6.34M | 1.61M |
| Operating Income | -8.50M | -8.50M | -7.09M | -15.75M | -13.19M | -6.22M |
| Interest Expense | -473.94K | -473.94K | -870.28K | -1.05M | -96.69K | |
| Interest & Investment Income | 32.10K | 32.10K | 5.47K | |||
| Other Non Operating Income (Expenses) | -280.00 | -280.00 | -13.37K | |||
| EBT Excluding Unusual Items | -8.94M | -8.94M | -7.97M | -16.80M | -13.28M | -6.22M |
| Pretax Income | -8.94M | -8.94M | -7.97M | -16.80M | -13.28M | -6.22M |
| Income Tax Expense | 7.99K | 7.99K | -3.26M | 22.42K | -12.20K | -786.52K |
| Earnings From Continuing Operations | -8.95M | -8.95M | -4.71M | -16.83M | -13.27M | -5.43M |
| Net Income | -8.95M | -8.95M | -4.71M | -16.83M | -13.27M | -5.43M |
| Net Income to Common | -8.95M | -8.95M | -4.71M | -16.83M | -13.27M | -5.43M |
| Shares Outstanding (Basic) | 37.36M | 37.36M | 39.49M | 29.34M | 22.26M | 15.06M |
| Shares Outstanding (Diluted) | 37.36M | 37.36M | 39.49M | 29.34M | 22.26M | 15.06M |
| EPS (Basic) | -0.24 | -0.24 | -0.12 | -0.57 | -0.60 | -0.36 |
| EPS (Diluted) | -0.24 | -0.24 | -0.12 | -0.57 | -0.60 | -0.36 |
| Free Cash Flow | -5.94M | -5.94M | -1.81M | -9.49M | -7.70M | -5.47M |
| Free Cash Flow Per Share | -0.16 | -0.16 | -0.05 | -0.32 | -0.35 | -0.36 |
| EBITDA | -8.50M | -8.50M | -7.09M | -15.75M | -13.18M | -6.22M |
| D&A For EBITDA | 1.82K | 1.82K | 2.56K | 3.87K | 3.80K | 2.33K |
| EBIT | -8.50M | -8.50M | -7.09M | -15.75M | -13.19M | -6.22M |
Balance sheet
Fiscal year April - March; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 14.59M | 14.59M | 1.56M | 826.85K | 4.05M | 2.70M |
| Short-Term Investments | 6.00M | 6.00M | ||||
| Cash & Short-Term Investments | 20.59M | 20.59M | 1.56M | 826.85K | 4.05M | 2.70M |
| Other Receivables | 170.67K | 170.67K | 1.89M | 580.94K | 980.08K | 883.43K |
| Receivables | 170.67K | 170.67K | 1.89M | 580.94K | 980.08K | 883.43K |
| Prepaid Expenses | 205.08K | 205.08K | 225.36K | 130.13K | 171.25K | 711.21K |
| Total Current Assets | 20.97M | 20.97M | 3.68M | 1.54M | 5.20M | 4.30M |
| Property, Plant & Equipment | 6.31K | 6.31K | 2.04K | 3.35K | 7.22K | 5.22K |
| Total Assets | 20.98M | 20.98M | 3.68M | 1.54M | 5.20M | 4.30M |
| Accounts Payable | 7.14M | 7.14M | 7.90M | 6.13M | 2.31M | 741.81K |
| Accrued Expenses | 1.50M | 1.50M | 378.58K | 1.19M | 2.65M | 611.38K |
| Short-Term Debt | 2.22M | |||||
| Other Current Liabilities | 1.33K | 1.33K | 948.32K | 103.83K | 73.20K | |
| Total Current Liabilities | 8.64M | 8.64M | 9.23M | 7.42M | 7.26M | 1.35M |
| Total Liabilities | 8.64M | 8.64M | 9.23M | 7.42M | 7.26M | 1.35M |
| Additional Paid-In Capital | 173.56M | 173.56M | 146.72M | 143.11M | 131.39M | 123.98M |
| Retained Earnings | -151.97M | -151.97M | -143.02M | -142.52M | -125.70M | -112.43M |
| Comprehensive Income & Other | -9.25M | -9.25M | -9.24M | -6.47M | -7.74M | -8.60M |
| Shareholders' Equity | 12.34M | 12.34M | -5.55M | -5.88M | -2.05M | 2.95M |
| Total Liabilities & Equity | 20.98M | 20.98M | 3.68M | 1.54M | 5.20M | 4.30M |
| Total Debt | 2.22M | |||||
| Net Cash (Debt) | 20.59M | 20.59M | 1.56M | 826.85K | 1.83M | 2.70M |
| Net Cash Per Share | 0.55 | 0.55 | 0.04 | 0.03 | 0.08 | 0.18 |
| Filing Date Shares Outstanding | 52.48M | 52.48M | 37.61M | 33.84M | 25.55M | 21.14M |
| Total Common Shares Outstanding | 52.48M | 52.48M | 36.02M | 33.34M | 25.52M | 21.14M |
| Working Capital | 12.33M | 12.33M | -5.55M | -5.88M | -2.06M | 2.94M |
| Book Value Per Share | 0.24 | 0.24 | -0.15 | -0.18 | -0.08 | 0.14 |
| Tangible Book Value | 12.34M | 12.34M | -5.55M | -5.88M | -2.05M | 2.95M |
| Tangible Book Value Per Share | 0.24 | 0.24 | -0.15 | -0.18 | -0.08 | 0.14 |
| Machinery | 15.01K | 15.01K | 10.50K | 10.47K | 15.31K | 9.78K |
Cash flow statement
Fiscal year April - March; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Net Income | -8.95M | -8.95M | -4.71M | -16.83M | -13.27M | -5.43M |
| Depreciation & Amortization | 1.82K | 1.82K | 2.56K | 3.87K | 3.80K | 2.33K |
| Loss (Gain) From Sale of Assets | -179.00 | |||||
| Stock-Based Compensation | 1.61M | 1.61M | 1.41M | 1.13M | 1.32M | 1.80M |
| Other Operating Activities | 2.04M | 2.04M | -147.88K | 3.53M | 311.76K | -814.90K |
| Change in Accounts Receivable | 27.38K | |||||
| Change in Accounts Payable | -641.02K | -641.02K | 1.72M | 2.23M | 3.78M | -249.09K |
| Change in Other Net Operating Assets | 10.91K | 10.91K | -90.40K | 440.26K | 167.72K | -802.15K |
| Operating Cash Flow | -5.94M | -5.94M | -1.81M | -9.49M | -7.70M | -5.47M |
| Capital Expenditures | -6.08K | -6.08K | -1.21K | -5.92K | -1.67K | |
| Investment in Securities | -6.00M | -6.00M | ||||
| Investing Cash Flow | -6.01M | -6.01M | -1.21K | -5.92K | -1.67K | |
| Short-Term Debt Issued | 2.00M | |||||
| Long-Term Debt Issued | 950.00K | |||||
| Total Debt Issued | 950.00K | 2.00M | ||||
| Net Debt Issued (Repaid) | 950.00K | 2.00M | ||||
| Issuance of Common Stock | 25.02M | 25.02M | 1.71M | 6.21M | 7.32M | 2.15M |
| Financing Cash Flow | 25.02M | 25.02M | 2.66M | 6.21M | 9.32M | 2.15M |
| Foreign Exchange Rate Adjustments | -47.99K | -47.99K | -109.55K | 63.50K | -277.54K | -872.14K |
| Net Cash Flow | 13.03M | 13.03M | 734.05K | -3.22M | 1.34M | -4.19M |
| Free Cash Flow | -5.94M | -5.94M | -1.81M | -9.49M | -7.70M | -5.47M |
| Free Cash Flow Per Share | -0.16 | -0.16 | -0.05 | -0.32 | -0.35 | -0.36 |
| Levered Free Cash Flow | -2.10M | -2.10M | -2.72M | -3.09M | -2.77M | -3.90M |
| Unlevered Free Cash Flow | -1.81M | -1.81M | -2.18M | -2.44M | -2.71M | -3.90M |
| Free Cash Flow After Leases | -5.94M | -5.94M | -1.81M | -9.49M | -7.70M | -5.47M |
| Cash Income Tax Paid | -1.95M | -1.95M | -2.00M | -199.15K | ||
| Change in Working Capital | -630.11K | -630.11K | 1.63M | 2.67M | 3.95M | -1.02M |
Ratios
Fiscal year April - March; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 77.14M | 84.49M | 43.10M | 49.52M | 33.67M | 108.58M |
| Enterprise Value | 56.55M | 80.46M | 42.11M | 47.69M | 32.97M | 103.46M |
| Last Close Price | 1.47 | 1.61 | 1.27 | 1.49 | 1.32 | 5.14 |
| PB Ratio | 6.25 | 6.85 | -7.77 | -8.42 | -16.40 | 36.84 |
| P/TBV Ratio | 6.25 | 6.85 | 36.84 | |||
| Debt / Equity Ratio | -1.08 | |||||
| Net Debt / Equity Ratio | -1.67 | -1.67 | 0.28 | 0.14 | 0.89 | -0.92 |
| Net Debt / EBITDA Ratio | 2.42 | 2.42 | 0.22 | 0.05 | 0.14 | 0.43 |
| Net Debt / FCF Ratio | 3.47 | 3.47 | 0.86 | 0.09 | 0.24 | 0.49 |
| Quick Ratio | 2.40 | 2.40 | 0.37 | 0.19 | 0.69 | 2.65 |
| Current Ratio | 2.43 | 2.43 | 0.40 | 0.21 | 0.72 | 3.17 |
| Return on Equity (ROE) | -263.78% | -263.78% | -2,968.51% | -131.55% | ||
| Return on Assets (ROA) | -43.09% | -43.09% | -169.87% | -291.87% | -173.43% | -68.30% |
| Return on Capital Employed (ROCE) | -68.90% | -68.90% | 127.80% | 267.90% | 642.30% | -211.00% |
| Earnings Yield | -16.30% | -10.59% | -10.92% | -33.98% | -39.41% | -5.00% |
| FCF Yield | -7.70% | -7.03% | -4.21% | -19.16% | -22.87% | -5.04% |
| Buyback Yield / Dilution | 5.40% | 5.40% | -34.57% | -31.84% | -47.74% | -45.55% |